Pulsatile perfusion

Pulsatile perfusion is a preservation strategy for kidneys recovered from HCV-positive donors, particularly when those organs are considered for transplantation into HCV RNA-positive recipients. Its decisive significance lies in treating preservation itself as a possible intervention against transmission: rather than merely keeping the organ viable until implantation, pulsatile pump perfusion may deplete virus from the kidney and thereby reduce the infectious burden carried into the recipient.

Definition and Transplant Setting

Pulsatile perfusion uses a pump to circulate preservation fluid through the procured kidney. In the transplantation of kidneys from HCV-positive donors, the technique is considered alongside recipient selection, donor–recipient genotype compatibility, and other measures intended to make transplantation safer. The recommendation is conditional rather than universal: when available, pulsatile perfusion is preferred to cold storage for preserving kidneys from HCV-positive donors.

The relevant clinical context is a recipient who already has HCV infection and end-stage renal disease. Such patients may benefit from transplantation despite the infection: kidney transplantation provides better survival than remaining on the waiting list, even though HCV-positive recipients have worse long-term patient and graft survival than HCV-negative recipients and face complications including post-transplant diabetes mellitus, post-transplant glomerulonephritis, proteinuria, and chronic allograft nephropathy. Pulsatile perfusion therefore belongs to a broader strategy of making otherwise usable HCV-positive organs available without treating viral transmission as an unavoidable cost.

Antiviral Effect on the Organ

The central reported effect of pulsatile pump perfusion is a reduction in HCV viral load within HCV-positive kidneys. This finding gives the technique a rationale beyond ordinary organ preservation: lowering the amount of virus present in the graft could reduce the probability or intensity of HCV transmission during transplantation. The evidence is presented as having the potential to reduce transmission, not as proof that transmission is eliminated.

The technique’s proposed benefit is especially important because pre-existing HCV infection does not reliably protect a recipient from reinfection or superinfection. A recipient carrying one HCV genotype may acquire another genotype from the donor kidney, and even infection with the same genotype does not guarantee protection. Donor–recipient genotype matching can increase safety, although time constraints may limit its practical use. Pulsatile perfusion offers a different protective point of intervention by attempting to decrease the viral burden in the organ before implantation.

Evidence and Limits

The supporting evidence comes from reports describing the transmission of HCV through kidney transplantation and the depletion of HCV from procured kidneys using pulsatile perfusion preservation. These studies established the technique as a plausible method for reducing the viral load of an HCV-positive graft. However, the reported findings had not been reproduced in more recent studies, so the recommendation remained cautious and pragmatic rather than definitive.

The available evidence consequently supports using pulsatile perfusion when feasible, not assuming that it makes an HCV-positive kidney virus-free. Its effect is one component of risk reduction and must be interpreted together with the recipient’s HCV RNA status, the possibility of genotype mismatch, post-transplant monitoring, and the general risks of transplantation under immunosuppression. The distinction matters because a lower graft viral load may reduce transmission risk without removing the possibility of superinfection or severe post-transplant liver disease.

Clinical and Policy Significance

Pulsatile perfusion changes the meaning of an HCV-positive donor kidney from a simple infectious hazard into a potentially manageable transplant resource. International recommendations increasingly supported safer use of these organs, while restricting them primarily to HCV RNA-positive recipients on the waiting list. In that framework, perfusion technology complements rather than replaces careful allocation and infectious-disease assessment.

Its significance is also economic and ethical. HCV-positive recipients generally fare better with transplantation than with continued waiting, yet HCV-positive kidneys may otherwise be treated as surplus organs. A preservation method that can reduce the graft’s viral load helps reconcile two competing obligations: protecting the recipient from avoidable infection while not discarding organs that could shorten waiting time and improve survival. The technique therefore represents a modest but consequential shift from excluding infected organs toward controlling the risks attached to their use.